Phase I Study to Determine the Safety, Infectivity, and Tolerability of Two Doses of Live Attenuated Recombinant Cold Passaged (cp) 45 Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3 102A, Delivered as Nose Drops to Infants 6 to 12 Months of Age.

Trial Profile

Phase I Study to Determine the Safety, Infectivity, and Tolerability of Two Doses of Live Attenuated Recombinant Cold Passaged (cp) 45 Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3 102A, Delivered as Nose Drops to Infants 6 to 12 Months of Age.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2011

At a glance

  • Drugs MEDI 560 (Primary)
  • Indications Influenza virus infections; Parainfluenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 08 Aug 2011 The study was originally designed to enroll infants aged 6-12 months; however, after results from cohort one were examined, the protocol was modified to includedchildren aged 6-36 months.
    • 08 Aug 2011 Results published in the Pediatric Infectious Disease Journal.
    • 15 Jul 2010 Actual end date (1 Apr 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top